HealthDay: Empagliflozin Offers Clinical Benefit in Heart Failure
For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.
Mikhail N. Kosiborod, MD, from Saint Luke's Mid America Heart Institute in Kansas City, Missouri, and colleagues conducted a secondary analysis to examine the impact of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life among patients hospitalized for acute heart failure.
"Our results are of clinical importance, because very few therapies have been previously shown to improve symptoms and functional status in the early postdischarge period in individuals hospitalized with acute heart failure," the authors write.
Read the full HealthDay article: Empagliflozin Offers Clinical Benefit in Heart Failure